2,022 research outputs found
_Online_Data_Supplement_Revised_Clean_copy – Supplemental material for Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill
No full textSupplemental material, _Online_Data_Supplement_Revised_Clean_copy for Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill by Mitchell S. Buckley, Kristen D. Knutson, Sumit K. Agarwal, Jake M. Lansburg, Laura M. Wicks, Rajeev C. Saggar, Emily C. Richards, Brian J. Kopp and Brian L. Erstad in Annals of Pharmacotherapy</p
sj-docx-4-aop-10.1177_10600280231160437 – Supplemental material for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS
No full textSupplemental material, sj-docx-4-aop-10.1177_10600280231160437 for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS by John W. Devlin, Sarah E. Train, Karen E. A. Burns, Anthony Massaro, Ting Ting Wu, Timothy Castor, John Vassaur, Kavitha Selvan, John P. Kress and Brian L. Erstad in Annals of Pharmacotherapy</p
sj-docx-2-aop-10.1177_10600280231160437 – Supplemental material for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS
No full textSupplemental material, sj-docx-2-aop-10.1177_10600280231160437 for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS by John W. Devlin, Sarah E. Train, Karen E. A. Burns, Anthony Massaro, Ting Ting Wu, Timothy Castor, John Vassaur, Kavitha Selvan, John P. Kress and Brian L. Erstad in Annals of Pharmacotherapy</p
sj-docx-3-aop-10.1177_10600280231160437 – Supplemental material for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS
No full textSupplemental material, sj-docx-3-aop-10.1177_10600280231160437 for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS by John W. Devlin, Sarah E. Train, Karen E. A. Burns, Anthony Massaro, Ting Ting Wu, Timothy Castor, John Vassaur, Kavitha Selvan, John P. Kress and Brian L. Erstad in Annals of Pharmacotherapy</p
sj-docx-1-aop-10.1177_10600280231160437 – Supplemental material for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS
No full textSupplemental material, sj-docx-1-aop-10.1177_10600280231160437 for Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS by John W. Devlin, Sarah E. Train, Karen E. A. Burns, Anthony Massaro, Ting Ting Wu, Timothy Castor, John Vassaur, Kavitha Selvan, John P. Kress and Brian L. Erstad in Annals of Pharmacotherapy</p
An Interview with Brian Fisak
No full textThe M.A. program in Clinical Psychology was first offered at the UCF Sanford/Lake Mary Regional Campus in Fall, 2013. Recently I had an opportunity to speak with one of the program faculty members, Dr. Brian Fisak, co-author along with Kellie Kissell, Hayley Rodriguez and Lloyd Lucas of the recently published article “Examination of the Contribution of Ruminative Thinking and Maladaptive Self-Beliefs to Social Anxiety”
Recommended from our members
Sotorasib Versus Docetaxel in Advanced Non-Small Cell Lung Cancer With Kras G12C Mutation: Cost-Effectiveness and Value of Information Analyses
No full textBackground: Sotorasib is a first-in-class oral KRAS G12C inhibitor and has shown improved safety and efficacy compared to docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have KRAS G12C mutation and have previously been treated.Objective: To estimate the cost-effectiveness of sotorasib compared to docetaxel in KRAS G12C mutated advanced NSCLC and to determine the cost of uncertainty and whether future research will be beneficial by estimating the expected value of perfect information (EVPI). Methods: A 3-state partitioned survival model (progression-free, progressed, death) over a time horizon of 5 years and from a payer perspective in the United States was developed. Estimates of the progression-free and overall survival were determined from the Kaplan-Meier curves of the CodeBreak 200 trial based on the best-fitting parametric distribution. Costs of drugs and subsequent systemic treatments were sourced from Redbook, administration costs from Physician Fee Schedule, cost of adverse events management, and utilities from published literature. Model outcomes included incremental cost, quality-adjusted life-year (QALY), and incremental cost-utility ratio (ICUR). One-way and probabilistic sensitivity analyses (PSA) were used to account for the uncertainties in the model. Discounting at 3% per year was utilized. Using results from the PSA, the net health benefits (NHBs) and net monetary benefits (NMBs) forgone and population EVPI were calculated. Results: Sotorasib yielded an increase of 0.35 QALYs at an incremental cost of 150,000 per QALY, the incremental cost per QALY gained (ICUR) was 150,000 WTP was 3% vs. 97% for sotorasib and docetaxel respectively. The average per-patient NHBs and NMBs forgone were 0.061QALYs and 627.3 million. Conclusion: Sotorasib may require a higher WTP threshold or a reduction in acquisition cost for it to be considered cost-effective. Additionally, uncertainty in its clinical efficacy compared to docetaxel persists, and future research to acquire additional evidence may be beneficial.Release after 11/06/202
Data supporting Thomas & Ratterman 2020 "Ozone depletion-induced climate change following a 50 pc supernova?"
No full textThis data supports publication Thomas & Ratterman 2020 "Ozone depletion-induced climate change following a 50 pc supernova?"
The paper can be found as a pre-print: https://arxiv.org/abs/2006.15079
Journal reference: "Ozone depletion-induced climate change following a 50 pc supernova", Brian C. Thomas and Cody L. Ratterman, Phys. Rev. Research 2, 043076 – Published 14 October 2020, doi: 10.1103/PhysRevResearch.2.043076 (https://journals.aps.org/prresearch/abstract/10.1103/PhysRevResearch.2.043076)
Data included here are selected (post-processed) output from the PlaSim climate model, in netCDF format. Full raw data may be obtained upon request of the first author (Brian Thomas [email protected])
Adventures in Historical Research
No full textLocal historian and author Brian Griffin discusses the excitement of exploring Bellingham’s history through archival research, including his work at the Center for Pacific Northwest Studies
Bridging scholarly theory and forensic practice: toward a more pedagogical model of rhetorical criticism
No full textBrian Ott was a professor in the Department of Speech Communication at Colorado State University.Includes bibliographical references (pages 71-74).In this essay, the author contends that competitors in the event of rhetorical criticism, or communication analysis (CA) as it is alternatively called, are locked into a model that poses serious questions about the educational value of the event. In an effort to narrow the ever widening gap between theory and practice and to heighten the pedagogical value of contest rhetorical criticism, the author proposes to chart briefly the chief features of the existing RC model, to identify the limitations posed by that model, and to suggest several viable alternatives
- …
